A prostate cancer diagnosis is not the end of a patient’s clinical story, it’s the beginning of a series of decisions that will define a patient’s treatment trajectory. Active surveillance or intervention? Hormone therapy or surgery? How aggressive, how urgent, how certain?
Molecular testing exists to answer those questions with precision. Yet, in many urology practices, the workflow surrounding these tests remains fragmented, slow, and prone to failure. Even though the capabilities have advanced, the infrastructure around it, in many cases, has not.
What Molecular Tests Actually Deliver
For urologists managing prostate cancer, molecular assays have become essential tools for risk stratification. Tests that evaluate gene expression, tumor biology, and genomic markers give clinicians something a standard pathology report cannot: a more complete picture of how a cancer is likely to behave.
That information directly:
- Informs treatment planning
- Supports more confident conversations with patients about surveillance versus intervention
- Reduces the risk of both overtreatment and undertreatment.
The clinical value is well-established. The gap lies in execution.
Where the Workflow Breaks Down
In a traditional pathology workflow, molecular test ordering is a separate process. It’s disconnected from the diagnostic workup, dependent on manual communication between the clinic, the lab, and the pathologist, and vulnerable to the kind of administrative friction that causes tests to be delayed, misfiled, or never ordered at all.
The tissue itself presents another challenge. A significant percentage of biopsy specimens fail to meet the quality threshold required for molecular analysis, receiving a “quantity not sufficient” (QNS) designation or returning with degraded RNA. Research has documented QNS rates as high as 23% in metastatic prostate cancer samples. When a specimen fails, the downstream consequences are substantial: delayed diagnoses, repeat biopsies, added cost, and lost time for the patient.
These are not edge cases. They are common systemic inefficiencies that erode the clinical value of molecular testing before the test ever runs.
An Integrated Approach Changes the Equation
Lumea was built around the principle that diagnostic tools should work together, not separately. Molecular test ordering is embedded directly into its digital pathology workflow: not as a separate portal or add-on system, but as a native part of how cases are managed from biopsy to sign-out.
This integration produces measurable results. Practices using Lumea’s platform are achieving molecular test turnaround times up to 50% faster. For patients awaiting a diagnosis, and for clinicians making time-sensitive treatment decisions, that compression in timeline is clinically significant.
Conditional ordering further reduces the risk of missed tests. Physicians can establish criteria in advance so that when a patient meets the threshold, the appropriate molecular test is automatically queued and routed, eliminating the reliance on manual follow-through at each step.
Lumea also addresses specimen quality at the point of collection. The BxBoard, Lumea’s tissue-handling device, uses a precision fixation method that has demonstrated a 2.1x reduction in specimen cancellation rates due to QNS and RNA degradation compared to traditional formalin bottles. Improved tissue preservation means fewer failed specimens, fewer repeat procedures, and more reliable data reaching the lab.
The Standard of Care Is Rising
Precision medicine in urology is quickly becoming the new standard. Patients and referring physicians alike expect that the diagnostic workup will be thorough, efficient, and actionable. Molecular testing is a core part of that standard, and the workflow supporting it needs to match.
Lumea’s platform is designed to make that possible: reducing turnaround times, eliminating dropped tests, improving specimen quality, and ensuring that every patient who should receive a molecular test actually does.
Explore Lumea’s Molecular Testing Partners
Lumea works with a curated network of molecular testing partners. To learn which tests are available through our platform and how integrated ordering could work in your practice, visit our partners page and connect with our team.
